Medicare Bundled Payment Policies Could Cut Amgen’s Parsabiv Sales By 50%
Executive Summary
Amgen ‘looks forward’ to working with CMS and Congress to shape Medicare reimbursement policies in a way that better ensures access.
You may also be interested in...
Medicare Dialysis Bundle And New Drugs: Will Transitional Payments Work For Korsuva, Vadadustat?
Quick provider uptake will be key for upcoming new drugs covered by the Medicare end stage renal disease prospective payment system.
AstraZeneca’s Roxadustat And The Challenge Of Shifting Medicare Coverage Policy
Though the policy environment can be 'uncertain,' AstraZeneca has 'good grasp' on how the anemia drug for patients with chronic kidney disease will be covered under the Medicare end-stage renal disease bundled payment system, senior VP for market access Rick Suarez says.
Medicare Add-On Payments For New Dialysis Drugs Limited To ‘Innovative’ Products
Centers for Medicare and Medicaid Services narrows the types of drugs eligible for add-on payments in the Medicare end-stage renal program as it tries to balance efforts to promote innovation with controlling costs.